04 April 2024
04 April 2024
Article doesn't exist
LNZ100 met the primary endpoints and key secondary endpoints in the Phase III CLARITY 1 and 2 trials.
The company anticipates reporting topline data from the study in the first half of next year.
The trial data indicated that etidronate treatment was safe without any adverse side effects observed.
The trial will assess the efficacy and safety of raludotatug deruxtecan in ovarian cancer patients.
The pulsed field ablation market in cardiovascular treatment is growing quickly.
Under the supply deal, MSD will provide the KEYTRUDA required for the trial.
Regarding the primary endpoint of treatment failure, results showed lower rates, which indicates a greater treatment benefit.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
